BioAtla, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jay Short
- Full Time Employees
- 61
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11085 Torreyana Road San Diego CA United States of America 92121
- IPO Date
- Dec 16, 2020
- CIK
- 0001826892
- Website
- bioatla.com
- Similar Companies
- Business
- BioAtla Inc (Nasdaq: BCAB), a clinical-stage biotechnology company founded in 2007 and headquartered in San Diego, California, with operations extending to Beijing, China, develops conditionally active biologic (CAB) antibody therapeutics designed for selective activation in the tumor microenvironment to treat solid tumors; its proprietary CAB platform enables the creation of antibody drug conjugates (ADCs), immuno-oncology agents, and bispecific T-cell engagers with improved therapeutic indices over conventional therapies. The company's lead pipeline candidates include mecbotamab vedotin (BA3011; CAB-AXL-ADC) targeting AXL in soft tissue sarcoma, NSCLC, and ovarian cancer; ozuriftamab vedotin (BA3021 or Oz-V; CAB-ROR2-ADC) targeting ROR2 in melanoma, head and neck cancer, NSCLC, and HPV-positive oropharyngeal squamous cell carcinoma; evalstotug (BA3071; CAB-CTLA-4) targeting CTLA-4 across multiple carcinomas including NSCLC, melanoma, renal cell carcinoma, and hepatocellular carcinoma; BA3182 (CAB-EpCAM x CAB-CD3 bispecific T-cell engager) for adenocarcinomas such as colorectal, NSCLC, ovarian, prostate, and triple-negative breast cancer; next-generation CAB-ADCs like BA3361 (Nectin-4) and BA3151 (B7-H4) for various solid tumors; and additional bispecifics including BA3142 (B7-H3 x CD3) and BA3311 (EGFR x CD3). Recent developments encompass FDA alignment achieved in 2025 on the Phase 3 registrational trial design for Oz-V in second-line-plus HPV-positive oropharyngeal squamous cell carcinoma with dual primary endpoints of overall response rate and survival to support accelerated and full approval, with trial initiation planned for early 2026 alongside a strategic partner; advancement of the Phase 1 BA3182 trial in advanced adenocarcinomas showing prolonged tumor control and manageable safety with data readout anticipated in first-half 2026; positive Phase 2 overall survival data for mecbotamab vedotin in sarcomas presented at SITC 2025; a September 2024 worldwide license agreement with Context Therapeutics for the CAB-Nectin-4 x CD3 T-cell engager (BA3362) yielding up to $133.5 million in milestones plus royalties and a $2 million payment received in October 2025; November 2025 agreements providing up to $22.5 million in flexible non-dilutive financing from Yorkville Advisors and Anson Advisors to support operations amid advanced negotiations for a year-end strategic partnership transaction; and a March 2025 workforce reduction contributing to lowered R&D and G&A expenses in Q3 2025.
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
BioAtla Announces Share Consolidation
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
BioAtla, Inc. (NASDAQ:BCAB) Sees Large Drop in Short Interest
Brokerages Set BioAtla, Inc. (NASDAQ:BCAB) Target Price at $4.00
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Drop in Short Interest
Mirum Pharmaceuticals (NASDAQ:MIRM) & BioAtla (NASDAQ:BCAB) Financial Comparison
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress